Y Song1, K He, E B Levitan, J E Manson, S Liu. 1. Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. ysong@hsph.harvard.edu
Abstract
AIMS: The aim of this study was to assess the evidence on the effect of oral magnesium supplementation on glycaemic control in patients with Type 2 diabetes. METHODS: We searched the electronic databases of medline, embase and the Cochrane Controlled Trials Register up to January 2005. We identified nine randomized double-blind controlled trials with a total of 370 patients with Type 2 diabetes and of duration 4-16 weeks. The median dose of oral magnesium supplementation was 15 mmol/day (360 mg/day) in the treatment groups. The primary outcome was glycaemic control, as measured by glycated haemoglobin (HbA(1c)) or fasting blood glucose levels; the secondary outcomes included body mass index, blood pressure (BP) and lipids. Using a random-effects model, we calculated the weighted mean differences (WMD) and 95% confidence interval (CI). RESULTS: After a median duration of 12 weeks, the weighted mean post-intervention fasting glucose was significantly lower in the treatment groups compared with the placebo groups [-0.56 mmol/l (95% CI, -1.10 to -0.01); P for heterogeneity = 0.02]. The difference in post-intervention HbA(1c) between magnesium supplementation groups and control groups was not significant [-0.31% (95% CI, -0.81 to 0.19); P for heterogeneity = 0.10]. Neither systolic nor diastolic BP was significantly changed. Magnesium supplementation increased on high-density lipoprotein (HDL) cholesterol levels [0.08 mmol/l (95% CI, 0.03 to 0.14); P for heterogeneity = 0.36] but had no effect on total cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride. CONCLUSIONS: Oral magnesium supplementation for 4-16 weeks may be effective in reducing plasma fasting glucose levels and raising HDL cholesterol in patients with Type 2 diabetes, although the long-term benefits and safety of magnesium treatment on glycaemic control remain to be determined.
AIMS: The aim of this study was to assess the evidence on the effect of oral magnesium supplementation on glycaemic control in patients with Type 2 diabetes. METHODS: We searched the electronic databases of medline, embase and the Cochrane Controlled Trials Register up to January 2005. We identified nine randomized double-blind controlled trials with a total of 370 patients with Type 2 diabetes and of duration 4-16 weeks. The median dose of oral magnesium supplementation was 15 mmol/day (360 mg/day) in the treatment groups. The primary outcome was glycaemic control, as measured by glycated haemoglobin (HbA(1c)) or fasting blood glucose levels; the secondary outcomes included body mass index, blood pressure (BP) and lipids. Using a random-effects model, we calculated the weighted mean differences (WMD) and 95% confidence interval (CI). RESULTS: After a median duration of 12 weeks, the weighted mean post-intervention fasting glucose was significantly lower in the treatment groups compared with the placebo groups [-0.56 mmol/l (95% CI, -1.10 to -0.01); P for heterogeneity = 0.02]. The difference in post-intervention HbA(1c) between magnesium supplementation groups and control groups was not significant [-0.31% (95% CI, -0.81 to 0.19); P for heterogeneity = 0.10]. Neither systolic nor diastolic BP was significantly changed. Magnesium supplementation increased on high-density lipoprotein (HDL) cholesterol levels [0.08 mmol/l (95% CI, 0.03 to 0.14); P for heterogeneity = 0.36] but had no effect on total cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride. CONCLUSIONS: Oral magnesium supplementation for 4-16 weeks may be effective in reducing plasma fasting glucose levels and raising HDL cholesterol in patients with Type 2 diabetes, although the long-term benefits and safety of magnesium treatment on glycaemic control remain to be determined.
Authors: Rebecca B Costello; Ronald J Elin; Andrea Rosanoff; Taylor C Wallace; Fernando Guerrero-Romero; Adela Hruby; Pamela L Lutsey; Forrest H Nielsen; Martha Rodriguez-Moran; Yiqing Song; Linda V Van Horn Journal: Adv Nutr Date: 2016-11-15 Impact factor: 8.701
Authors: Mei Chung; Ethan M Balk; Stanley Ip; Gowri Raman; Winifred W Yu; Thomas A Trikalinos; Alice H Lichtenstein; Elizabeth A Yetley; Joseph Lau Journal: Am J Clin Nutr Date: 2009-02-25 Impact factor: 7.045
Authors: Liana C Del Gobbo; Fumiaki Imamura; Jason H Y Wu; Marcia C de Oliveira Otto; Stephanie E Chiuve; Dariush Mozaffarian Journal: Am J Clin Nutr Date: 2013-05-29 Impact factor: 7.045
Authors: Adela Hruby; Julius S Ngwa; Frida Renström; Mary K Wojczynski; Andrea Ganna; Göran Hallmans; Denise K Houston; Paul F Jacques; Stavroula Kanoni; Terho Lehtimäki; Rozenn N Lemaitre; Ani Manichaikul; Kari E North; Ioanna Ntalla; Emily Sonestedt; Toshiko Tanaka; Frank J A van Rooij; Stefania Bandinelli; Luc Djoussé; Efi Grigoriou; Ingegerd Johansson; Kurt K Lohman; James S Pankow; Olli T Raitakari; Ulf Riserus; Mary Yannakoulia; M Carola Zillikens; Neelam Hassanali; Yongmei Liu; Dariush Mozaffarian; Constantina Papoutsakis; Ann-Christine Syvänen; André G Uitterlinden; Jorma Viikari; Christopher J Groves; Albert Hofman; Lars Lind; Mark I McCarthy; Vera Mikkilä; Kenneth Mukamal; Oscar H Franco; Ingrid B Borecki; L Adrienne Cupples; George V Dedoussis; Luigi Ferrucci; Frank B Hu; Erik Ingelsson; Mika Kähönen; W H Linda Kao; Stephen B Kritchevsky; Marju Orho-Melander; Inga Prokopenko; Jerome I Rotter; David S Siscovick; Jacqueline C M Witteman; Paul W Franks; James B Meigs; Nicola M McKeown; Jennifer A Nettleton Journal: J Nutr Date: 2013-01-23 Impact factor: 4.798
Authors: Daniel T Dibaba; Pengcheng Xun; Yiqing Song; Andrea Rosanoff; Michael Shechter; Ka He Journal: Am J Clin Nutr Date: 2017-07-19 Impact factor: 7.045